CHEMM ChemoMetec

Opjustering af omsætning og driftsresultat

Opjustering af omsætning og driftsresultat

MEDDELELSE NR. 285

3. december 2024



Opjustering af omsætning og driftsresultat

ChemoMetec har i andet kvartal af regnskabsåret 2024/25 fortsat sin positive udvikling, hvor salget og ordretilgangen har udviklet sig bedre end forventet.

På baggrund heraf forventes der nu en omsætning i regnskabsåret 2024/25 på DKK 460-475 mio. mod senest udmeldt DKK 445-460 mio., og EBITDA forventes at ligge i intervallet DKK 230-240 mio. mod senest udmeldt DKK 222-230 mio. 

ChemoMetecs regnskab for første halvår 2024/25 forventes offentliggjort onsdag den 5. februar 2025.



Yderligere oplysninger

Martin Helbo Behrens, CEO

Telefon: (+45) 48 13 10 20

Kim Nicolajsen, CFO

Telefon (+45) 48 13 10 20



Om ChemoMetec A/S

ChemoMetec udvikler, producerer og markedsfører instrumenter til celletælling og en lang række andre målinger.

ChemoMetecs instrumenter markedsføres globalt inden for blandt andet farma, biotek og landbrug. ChemoMetec har nogle af verdens førende medicinalvirksomheder blandt sine kunder.

ChemoMetec blev etableret i 1997 og er børsnoteret på Nasdaq Copenhagen. Se også



EN
03/12/2024

Underlying

CHEMMChemoMetec

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ChemoMetec

Free Trial
CHEMM CHEMOMETEC

ChemoMetec A S: 1 director

A director at ChemoMetec A S bought 865 shares at 574.030DKK and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

12h / 11m 12h / 11m 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Notification of managers' transactions

Notification of managers' transactions ANNOUNCEMENT NO. 288 10 February 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of the Chair of ChemoMetec’s Board of Directors Niels Thestrup in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 1...

February 10, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
CHEMM CHEMOMETEC

ChemoMetec (Buy, TP: DKK675.00) - Growth that counts

ChemoMetec again reported solid results, well above expectations, despite its raised guidance in January, which looks increasingly conservative. It was notably a broad-based beat, with all product segments exceeding expectations. We are especially encouraged by the continued solid rebound in Instrument sales, helped by recent product launches. Margins were also strong (especially versus consensus), suggesting robust operating leverage. We reiterate our BUY and have increased our target price to ...

02/06/25 February 6, 2025 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

1. halvår 2024/25 - Godt første halvår med vækst i både omsætning og d...

1. halvår 2024/25 - Godt første halvår med vækst i både omsætning og driftsresultat MEDDELELSE NR. 2875. februar 2025 Godt første halvår med vækst i både omsætning og driftsresultat  Martin Helbo Behrens, CEO: Fremgangen er fortsat i 2. kvartal 2024/25, og i 1. halvår steg omsætningen til DKK 251,5 mio., svarende til en vækst på 26% sammenlignet med samme periode sidste år. Væksten var blandt andet drevet af enkelte større ordrer på de nye XcytoMatic-instrumenter i kølvandet på de igangsatte kundevalideringer i foråret 2024. I 1. halvår har vi samtidig fastholdt vores kommercielle fo...

February 5, 2025 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Interim report 2024/25 - Solid H1 performance driven by growth in both...

Interim report 2024/25 - Solid H1 performance driven by growth in both revenue and earnings ANNOUNCEMENT NO. 2875 February 2025 Solid H1 performance driven by growth in both revenue and earnings Martin Helbo Behrens, CEO: The growth continued in the second quarter of 2024/25, and revenue for the first half of the year was up to DKK 251.5 million, a year-on-year increase of 26%. Growth was supported by a few large orders for the new XcytoMatic instruments in the wake of the customer validations initiated in the spring of 2024. Concurrently, we maintained our commercial focus in the f...

February 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch